Exelixis (NASDAQ:EXEL) Price Target Raised to $35.00

Exelixis (NASDAQ:EXEL) had its price target upped by research analysts at Wells Fargo & Company from $30.00 to $35.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target points to a potential downside of 17.28% from the stock’s previous close.

Several other equities research analysts also recently weighed in on EXEL. Citigroup downgraded Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. HC Wainwright reiterated a “buy” rating and issued a $52.00 target price on shares of Exelixis in a research report on Tuesday, February 3rd. Guggenheim cut Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. Truist Financial set a $51.00 price objective on Exelixis in a research note on Wednesday, January 14th. Finally, Bank of America downgraded shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price on the stock. in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $46.47.

Exelixis Price Performance

Shares of EXEL stock traded down $0.67 on Wednesday, hitting $42.31. 609,624 shares of the company’s stock were exchanged, compared to its average volume of 2,528,341. The company has a 50 day moving average of $43.69 and a 200 day moving average of $40.92. The stock has a market cap of $11.34 billion, a P/E ratio of 17.72, a price-to-earnings-growth ratio of 0.74 and a beta of 0.42. Exelixis has a 12 month low of $32.38 and a 12 month high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same quarter in the previous year, the firm earned $0.55 earnings per share. The business’s quarterly revenue was up 5.6% on a year-over-year basis. Sell-side analysts predict that Exelixis will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 28,043 shares of the stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $42.58, for a total transaction of $1,194,070.94. Following the completion of the sale, the executive vice president directly owned 374,029 shares in the company, valued at approximately $15,926,154.82. This trade represents a 6.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 72,230 shares of company stock worth $3,046,923 over the last quarter. Corporate insiders own 2.85% of the company’s stock.

Institutional Investors Weigh In On Exelixis

Institutional investors and hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC lifted its stake in Exelixis by 21.6% in the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock valued at $805,412,000 after buying an additional 3,466,000 shares during the period. Assetmark Inc. grew its position in shares of Exelixis by 1,230.8% during the 3rd quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock worth $131,994,000 after buying an additional 2,955,813 shares during the period. Norges Bank bought a new stake in shares of Exelixis in the 2nd quarter valued at $122,099,000. Qube Research & Technologies Ltd lifted its position in shares of Exelixis by 120.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock valued at $134,306,000 after acquiring an additional 1,665,110 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Exelixis by 42.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after acquiring an additional 1,580,567 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: EPS and profitability beat — Exelixis reported Q4 EPS above consensus and delivered higher operating profit, net income and improved margins, which supports near‑term earnings power. Exelixis Q4 results press release
• Positive Sentiment: Strong cash generation and balance sheet improvement — operating cash flow rose materially and cash balances increased year‑over‑year, reducing leverage and supporting R&D/commercial investments. QuiverQuant financials snapshot
• Positive Sentiment: Commercial upside from CABOMETYX and pipeline timing — management highlighted the CABOMETYX franchise at ~$2.12B and reiterated a planned 2026 launch for zanzalintinib, which investors view as a multi‑year growth driver if approvals and uptake meet expectations. MSN: CABOMETYX franchise and zanzalintinib
• Neutral Sentiment: Analyst sentiment remains broadly constructive — several firms have Buy/outperform ratings and some raised targets, supporting medium‑term upside, though targets vary. TipRanks: analyst view
• Negative Sentiment: Revenue missed expectations — total Q4 revenue fell short of consensus, and that top‑line miss appears to be the main driver of the intraday weakness as investors weigh growth sustainability. QuiverQuant: revenue miss
• Negative Sentiment: Insider selling and mixed price targets — recent insider stock sales and a wide range of analyst targets (some notably low) add near‑term sentiment pressure and increase focus on upcoming commercial readouts and guidance. QuiverQuant: insider & targets
• Neutral Sentiment: Earnings call details available — the full Q4 earnings call transcript and slide deck provide management commentary on 2026 priorities; investors should review guidance/assumptions for clarity on growth expectations. Seeking Alpha: earnings call transcript

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.